Search results
Showing 16 to 30 of 35 results for abiraterone
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
data on the effectiveness of enzalutamide after previous treatment with abiraterone. Any explanatory notes(if applicable) The use of...
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
In development Reference number: GID-TA10904 Expected publication date: 03 December 2025
relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and...
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
In development Reference number: GID-TA11583 Expected publication date: TBC
Awaiting development Reference number: GID-TA11558 Expected publication date: TBC
Awaiting development Reference number: GID-TA11827 Expected publication date: TBC
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Discontinued Reference number: GID-TA10465
In development Reference number: GID-TA10696 Expected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
In development Reference number: GID-TA10779 Expected publication date: TBC
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.